Theravance Biopharma
TBPH
#6107
Rank
$0.44 B
Marketcap
Cayman Islands
Country
$9.22
Share price
-2.54%
Change (1 day)
-18.12%
Change (1 year)
Categories
Revenue for Theravance Biopharma (TBPH)
Revenue in 2023 (TTM): $57.42 M
According to Theravance Biopharma 's latest financial reports the company's current revenue (TTM) is $57.42 M. In 2022 the company made a revenue of $51.34 M a decrease over the years 2021 revenue that were of $55.31 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Theravance Biopharma from 2013 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $57.42 M | 11.84% |
| 2022 | $51.34 M | -7.17% |
| 2021 | $55.31 M | -23.03% |
| 2020 | $71.85 M | -2.12% |
| 2019 | $73.41 M | 21.61% |
| 2018 | $60.37 M | 292.37% |
| 2017 | $15.38 M | -68.37% |
| 2016 | $48.64 M | 15.48% |
| 2015 | $42.12 M | 260.42% |
| 2014 | $11.68 M | 5071.68% |
| 2013 | $0.22 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Corcept Therapeutics
CORT | $0.48 B | 740.02% | 🇺🇸 USA |
 Collegium Pharmaceutical
COLL | $0.56 B | 886.99% | 🇺🇸 USA |
 Catalyst Pharmaceuticals CPRX | $0.39 B | 593.45% | 🇺🇸 USA |
 Catalent CTLT | $4.09 B | 7,036.39% | 🇺🇸 USA |